

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/521,534-Conf. #8954
				Filing Date	August 31, 2005
				First Named Inventor	Peter Serno
				Art Unit	1615
				Examiner Name	H. N. Sheikh
Sheet	1	of	11	Attorney Docket Number	LeA35683 [83964(303989)]

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AD	2,705,715	04/05/1955	Baker et al.	
	AE	3,036,070	05/22/1962	Druey et al.	
	AF	3,169,129	02/09/1965	Rodgers et al.	
	AG	3,331,840	07/18/1967	Fry et al.	
	AH	RE26565	04/29/1969	Rodgers et al.	
	AI	4,039,544	08/02/1977	Broughton et al.	
	AJ	4,052,390	10/04/1977	Broughton et al.	
	AK	4,060,615	11/29/1977	Matier et al.	
	AL	4,159,330	06/26/1979	Doria et al.	
	AM	4,167,568	09/11/1979	Knowles et al.	
	AN	4,379,788	04/12/1983	Heider et al.	
	AO	4,431,440	02/14/1984	Bhalla et al.	
	AP	4,666,908	05/19/1987	Hamilton	
	AQ	4,885,301	12/05/1989	Coates	
	AR	4,923,874	05/08/1990	McMahon et al.	
	AS	5,047,404	09/10/1991	Coates et al.	
	AT	5,073,559	12/17/1991	Coates	
	AU	5,075,310	12/24/1991	Coates et al.	
	AV	5,147,875	09/15/1992	Coates et al.	
	AW	5,250,534	10/05/1993	Bell et al.	
	AX	5,254,571	10/19/1993	Coates et al.	
	AY	5,272,147	12/21/1993	Bell et al.	
	AZ	5,294,612	03/15/1994	Bacon et al.	
	AAA	5,316,906	05/31/1994	Haughland et al.	
	AAB	5,346,901	09/13/1994	Bell et al.	
	AAC	5,426,107	06/20/1995	Bell et al.	
	AAD	5,482,941	01/09/1996	Terrett	
	AAE	5,591,742	01/07/1997	Bell et al.	
	AAF	5,719,283	02/17/1998	Bell et al.	
	AAG	5,374,053	03/31/1998	Terret	
	AAH	2004/152700	08/05/2004	Niewohner et al.	
	AAI	6,143,746	11/07/2000	Daugan et al.	
	AAJ	2002/128171	09/12/2002	Watkins et al.	
	AAK	6,362,178	03/26/2002	Niewohner et al.	
	AAL	2007/0004744	01/04/2007	Kreisel	
	AAM	6,566,360	05/2003	Niewohner et al.	
	AAN	2004/0152700	08/05/2004	Niewohner	
	AAO	2006/0111354	05/25/2006	Serno	
	AAP	6,221,402	04/24/2001	Itoh	
	AAQ	6,980,922	05/10/2005	Niewohner	
	AAR	2002/0002172	01/03/2002	Bell-Huff	
	AAS	2003/0134861	07/17/2003	Doherty	
	AAT	5,552,152	09/03/1996	Shen	
	AAU	2004/0109890	06/10/2004	Sugimoto et al.	
	AAV	2004/0043996	03/34/2004	Nackarni	
	AAW	2002/0119195	08/29/2002	Sen et al.	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/521,534-Conf. #8954
				Filing Date	August 31, 2005
				First Named Inventor	Peter Serno
				Art Unit	1615
				Examiner Name	H. N. Sheikh
Sheet	2	of	11	Attorney Docket Number	LeA35683 [83964(303989)]

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AAX	2008/0268046	10/2008	Zuleger et al.	
	AAY	6,503,908	01/2003	Maw et al.	
	AAZ	6,075,028	06/2000	Graham	
	AAAA	5,556,847	09/1996	Johnson et al.	
	AAAB	6,943,163	09/2005	Niewohner et al.	
	AAAC	7,091,203	08/2006	Niewohner	
	AAAD	3,941,785	03/02/1976	Clark et al.	
	AAAE	3,840,537	10/08/1974	Garside et al.	
	AAAF	3,333,961	08/01/1967	Fry et al.	
	AAAG	4,278,673	07/14/1981	Hartley et al.	
	AAAH	6,100,270	08/08/2000	Campbell	
	AAAI	7,122,540	10/17/2006	Niewohner et al.	
	AAAJ	7,314,871	01/01/2008	Niewohner et al.	
	AAAK	3,941,785	03/1976	Clarke et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/521,534-Conf. #8954
				Filing Date	August 31, 2005
				First Named Inventor	Peter Serno
				Art Unit	1615
				Examiner Name	H. N. Sheikh
Sheet	3	of	11	Attorney Docket Number	LeA35683 [83964(303989)]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)				
	BD	BE865125	09/21/1978	Allen Hanburys Ltd		
	BE	DE2255172	05/24/1973	Allen Hanburys Ltd		
	BF	DE2811780	09/28/1978	Allen Hanburys Ltd		
	BG	DE2364076	07/18/1994	Allen Hanburys Ltd		
	BH	EP0009384	04/02/1980	Glaxo Group Ltd		
	BI	EP0162715	11/27/1985	Sankyo Company Ltd		
	BJ	EP0201188	12/17/1986	Warner Lambert Co		
	BK	EP0293063	11/30/1988	Smith Kline French Lab		
	BL	EP0347146	12/20/1989	Smith Kline French Lab		
	BM	EP0349239	01/03/1990	Smith Kline French Lab		
	BN	EP0351058	01/17/1990	Smith Kline French Lab		
	BO	EP0352960	09/31/1990	Smith Kline French Lab		
	BP	EP0371731	06/06/1990	Smith Kline French Lab		
	BQ	EP0442204	08/21/1991	Smith Kline French Lab		
	BR	EP0463756	01/02/1992	Pfizer Ltd.		
	BS	EP0526004	02/03/1993	Pfizer Ltd.		
	BT	EP0636626	02/01/1995	Glaxo Lab SA		
	BU	EP0669324	08/30/1995	Eisai Co Ltd.		
	BV	EP0702555	03/26/1996	Pfizer Ltd.		
	BW	EP0812845	12/17/1997	Pfizer Ltd.		
	BX	GB1338235	1/21/1973	May Baker Ltd.		
	BY	WO9306104	04/01/1993	Pfizer Ltd.		
	BZ	WO9307149	04/15/1993	Pfizer Ltd.		
	BAA	WO9312095	06/24/0993	Pfizer Ltd.		
	BAB	WO9400453	01/06/1994	Pfizer Ltd.		
	BAC	WO9405661	03/17/1994	Pfizer Ltd.		
	BAD	WO9429277	12/22/1994	Smithklone Beecham PLC		
	BAE	WO9703675	02/06/1997	Glaxo Wellcome Lab SA		
	BAF	WO0260422	08/08/2002	Pfizer Limited		
	BAG	WO0024383	04/05/2000	Pfizer Research And Development Company, N.V./S.A.		
	BAH	WO0177110	10/18/2001	Novartis AG		
	BAI	WO9924433	05/20/1999	Bayer Aktiengesellschaft		
	BAJ	EP1097711	05/09/2001	Pfizer Limited		
	BAK	WO0151042	07/19/2001	Pfizer Limited		
	BAL	WO04108062	12/16/2004	Universitaetsklinikum		
	BAM	EP1074258	02/07/2001	Pfizer Products Inc.		
	BAN	WO03063875	08/07/2003	Pfizer Limited		
	BAO	WO01/05386	01/25/2001	Simon Shmuel		
	BAP	WO03063875	08/2003	R. P. Butt et al.		
	BAQ	WO0151042	07/19/2001	Pfizer Limited		
	BAR	DE10232113	01/29/2004	Bayer AG		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/521,534-Conf. #8954
				Filing Date	August 31, 2005
				First Named Inventor	Peter Serno
				Art Unit	1615
				Examiner Name	H. N. Sheikh
Sheet	4	of	11	Attorney Docket Number	LeA35683 [83964(303989)]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)				
	BAS	WO05110419	11/24/2005	Bayer HealthCare AG		
	BAT	WO0024383	05/04/2000	Pfizer R&D Co. N.V./ S.A.		
	BAU	EP1413294	04/28/2004	Yamanouchi Pharma Co. Ltd.		
	BAV	EP1120120	08/01/2001	Eisai Co. Ltd.		
	BAW	WO0042992	07/27/2000	Lavipharm Laboratories, Inc.		
	BAX	WO03051338	06/26/2003	SPI Pharma, Inc.		
	BAY	WO9323017	11/25/1993	Janssen Pharmaceutica, Inc.		
	BAZ	WO9924433	05/20/1999	Bayer Aktiengesellschaft		
	BBA	WO04012702	02/12/2004	Pharmacia Ab et al.		
	BBB	WO05110419	11/24/2005	Bayer HealthCare Ag et al.		
	BBC	WO06092207	09/08/2006	Bayer HealthCare Ag et al.		
	BBD	DE10232113	01/29/2004	Bayer Ag		
	BBE	DE19540642	07/05/1997	Stief et al.		
	BBF	WO0117480	03/15/2001	Androsolutions Inc.		
	BBG	WO05105073	11/10/2005	Medicnova Inc.		
	BBH	WO9926946	06/03/1999	Mochida Pharm Co. Ltd.		
	BBI	DE19812462	09/30/1999	Bayer AG		
	BBJ	WO0127101	04/19/2001	Pfizer Limited		
	BBK	WO0147928	07/05/2001	Bayer AG		
	BBL	WO0209713	02/07/2002	Bayer AG		
	BBM	WO0119357	03/22/2001	Bayer AG		
	BBN	GB790762	02/19/1958	Poole et al.		
	BBO	WO9616657	06/06/1996	Pfizer Ltd.		
	BBP	WO9428902	12/22/1994	Pfizer Ltd.		
	BBQ	GB1584461	02/11/1981	Hartley et al.		
	BBR	WO0264593	08/2002	Bayer AG		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/521,534-Conf. #8954
				Filing Date	August 31, 2005
				First Named Inventor	Peter Serno
				Art Unit	1615
				Examiner Name	H. N. Sheikh
Sheet	5	of	11	Attorney Docket Number	LeA35683 [83964(303989)]

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CF	H. S. Ahn et al.: "Calcium-Calmodulin-Stimulated and Cyclic-GMP-Specific Phosphodiesterases," Advances in Second Messenger and Phosphoprotein Research, 25: pp. 271-284 (1992)	
	CG	W. J. Aronson et al.: "The Role of Nitric Oxide and Cyclic GMP in Mediating Pelvic Nerve Stimulation Induced Erection in Dogs," J. Urology, 147: 454A (1992)	
	CH	K. M. Azadzi et al.: "Diabetes Mellitus Impairs Neurogenic and Endothelium-Dependent Relaxation of Rabbit Corpus Cavernosum Smooth Muscle," J. Urol. 148: 1587-1591 (Nov. 1992)	
	CI	K. M. Azadzi et al.: "Endothelium-Derived Nitric Oxide and Cyclooxygenase Products Modulate Corpus Cavernosum Smooth Muscle Tone," J. Urol. 147: 220-225 (Jan. 1992)	
	CJ	K. M. Azadzi et al.: "Hypercholesterolemia Impairs Endothelium-Dependent Relaxation of Rabbit Corpus Cavernosum Smooth Muscle," J. Urol., 146: 238-240 (Jul. 1991)	
	CK	J. A. Beavo: "Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms," Physiological Reviews, 75(4): 725-748 (Oct. 1995)	
	CL	J. A. Beavo et al.: "Multiple Cyclic Nucleotide Phosphodiesterase," Mol. Pharmacol., 46: 399-405 (1994)	
	CM	J. A. Beavo et al.: "Primary Sequence of Cyclic Nucleotide Phosphodiesterase Isozymes and the Design of Selective Inhibitors," TIPS, 11: 150-155 (Apr. 1990)	
	CN	A. Bowman et al.: "Cyclic GMP Mediates Neurogenic Relaxation in the Bovine Retractor Penis Muscle," Br. J. Pharmac., 81: 665-674 (1984)	
	CO	A. Burger: "Relation of Chemical Structure and Biological Activity," Med. Chem., 2 nd Ed., Interscience Publishers, inc., New York, pp. 36-45, (1960)	
	CP	M. A. Bush, : "The Role of the L-Arginine-Nitric Oxide-Cyclic GMP Pathway in Relaxation of Corpus Cavernosum Smooth Muscle," PhD Thesis, University of California, Los Angeles (1993)	
	CQ	P. A. Bush et al.: "Biosynthesis of Nitric Oxide and Citrulline from L-Arginine by Constitutive Nitric Oxide Synthase Present in Rabbit Corpus Cavernosum," Biochem & Biophys. Res. Comm., 186(1): 308-314 (Jul. 1992)	
	CR	P. A. Bush et al.: "Comparison of Nonadrenergic, Noncholinergic- and Nitric Oxide-Mediated Relaxation of Corpus Cavernosum," Int. J. Impotence Res., 4: 85-93 (1992)	
	CS	P. A. Bush et al.: "Nitric Oxide is a potent Relaxant of Human and Rabbit Corpus Cavernosum," J. Urology, 147: 1650-1655 (Jun. 1992)	
	CT	B. Dumaitre et al.: "Synthesis and Cyclic GMP Phosphodiesterase Inhibitory Activity of a Series of 6-Phenylpyrazolo[3,4-d]pyrimidones," J. Med. Chem., 39: 1635-1644 (1996)	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/521,534-Conf. #8954
				Filing Date	August 31, 2005
				First Named Inventor	Peter Serno
				Art Unit	1615
				Examiner Name	H. N. Sheikh
Sheet	6	of	11	Attorney Docket Number	LeA35683 [83964(303989)]

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CU	Goodman and Gilman's, <i>The Pharmacological Basis of Therapeutics</i> , Ed. Gilman, et al., McGraw Hill, 8 th Ed., (1990), pp. 33-43	
	CV	H. W. Hamilton et al.: "Synthesis and Structure-Activity Relationship of Pyrazolo[4,3-d]pyrimidin-7-ones as Adenosine Receptor Antagonists," J. Med. Chem., 30: 91-96 (1987)	
	CW	F. Holmquist et al.: "Actions of 3-Morpholinysynonimin (SIN-1) on Rabbit Isolated Penile Erectile Tissue," J. Urology, 150:1310-1315 (Oct. 1993)	
	CX	F. Holmquist et al.: "Effects of the Nitric Oxide Synthase Inhibitor N ^c – Nitro-L-Arginine on the Erectile Response to Cavernosum Nerve Stimulation in the Rabbit," Acta Physiol. Scand., 143: 299-304 (1991)	
	CY	L. J. Ignarro et al.: "Neurotransmitter Identity Doubt," Nature, 347: 131 (Sep. 1990)	
	CZ	L. J. Ignarro et al.: "Nitric Oxide and Cyclic GMP Formation upon Electrical Field Stimulation Cause Relaxation of Corpus Cavernosum Smooth Muscle," Biochem & Biophys. Res. Comm., 170(2): 843-850 (Jul. 1990)	
	CAA	N. Kim et al.: "Oxygen Tension Regulates the Nitric Oxide Pathway Physiological Role in Penile Erection," J. Clin. Invest., 91: 437-442 (Feb. 1993)	
	CAB	N. Kim et al.: "A Nitric Oxide-like Factor Mediates Nonadrenergic-Noncholinergic Neurogenic Relaxation of Penile Corpus Cavernosum Smooth Muscle," J. Clin. Inv., 88: 112-118 (Jul. 1991)	
	CAC	S. G. Korenman et al.: "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," JAGS, 41(d): 363-366 (Apr. 1993)	
	CAD	S. J. Lee et al.: "Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities," J. Med. Chem., 38: 3547-3557 (1995)	
	CAE	R. T. Morrison and R. N. Boyd: <i>Organic Chemistry</i> , Allyn and Bacon, Inc., 3 rd Ed., 1972), pp. 858-859	
	CAF	K. J. Murray: "Phosphodiesterase VA Inhibitors," 6(3): 150-156 (Apr. 1993)	
	CAG	C. D. Nicholson et al.: "Differential Modulation of Tissue Function and Therapeutic Potential of Selective inhibitors of Cyclic Nucleotide Phosphodiesterase Isoenzymes," TIPS, 12: 19-27 (Jan. 1991)	
	CAH	J. Rajfer et al.: "Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission," The New England Journal of Medicine, 326(2): 90-94 (Jan. 1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/521,534-Conf. #8954
				Filing Date	August 31, 2005
				First Named Inventor	Peter Serno
				Art Unit	1615
				Examiner Name	H. N. Sheikh
Sheet	7	of	11	Attorney Docket Number	LeA35683 [83964(303989)]

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CAI	I. Saenz de Tejada et al.: "Cholinergic Neurotransmission in Human Corpus Cavernosum. I. Responses of Isolated Tissue," Am. J. Physiol., 254: H459-H467		
	CAJ	I. Saenz de Tejada et al.: "Impaired Neurogenic and Endothelium-Mediated Relaxation of Penile Smooth Muscle from Diabetic Men with Impotence," N. Engl. Med., 320: 1025-1030 (Apr. 1989)		
	CAK	P. J. Silver et al.: "Cyclic GMP Potentiation by WIN 58237, a Novel Cyclic Nucleotide Phosphodiesterase Inhibitor," Journal of Pharmacology and Experimental Therapeutics, 271(3): 1143-1149 (1994)		
	CAL	C. G. Stief et al.: "Cyclic Nucleotide Phosphodiesterase (PDE) Isoenzymes in Human Cavernous Smooth Muscle: Characterization and Functional Effects of PDE-Inhibitors in Vitro and In Vivo," Int. J. Impot. Res. 7(1): 03 (Sep. 1995)		
	CAM	E. J. Sybertz et al.: "cGMP Phosphodiesterase Inhibition: A New Mechanism for the Discovery of Therapeutics Agents," Current Pharma. Design. 1(4): 373-390 (1995)		
	CAN	A. Taher et al.: "Cyclic Nucleotide Phosphodiesterase in human Cavernous Smooth Muscle," World J. Urol., 15: 32-35 (1997)		
	CAO	A. Taher et al.: "Phosphodiesterase Activity in Human Cavernous Tissue and the Effect of Various Selective Inhibitors," J. Urology, 149(4): 285 (Apr. 1993)		
	CAP	A. Taher et al.: "Cyclic Nucleotide Phosphodiesterase Activity in Human Cavernous Smooth Muscle and the Effect of Various Selective Inhibitors," Int. J. Impotence Res., 4(2): 11 (1992)		
	CAQ	Y. Takase et al.: "The Quinazole Derivatives as Novel Potent and Selective Inhibitors of Cyclic GMP-Phosphodiesterase," 206 th American Chemical Society National Meeting, Chicago, IL (1993)		
	CAR	W. J. Thompson: "Cyclic Nucleotide Phosphodiesterases: Pharmacology, Biochemistry and Functions," Pharmac. Ther., 5: 13-33 (1991)		
	CAS	T. J. Torphy et al.: "Characterization and Selective Inhibition of Cyclic Nucleotide Phosphodiesterase Isozymes in Canine Tracheal Smooth Muscle," Molecular Pharmacology, 37: 206-214 (1989)		
	CAT	A. J. Trapani et al.: "Hemodynamic Basis for the Depressor Activity of Zaprinast, a Selective Cyclic GMP Phosphodiesterase Inhibitor," J. Pharmacol. & Exp. Ther., 258: 269-274 (1991)		
	CAU	F. Trigo-Rocha et al.: "The Effect of Intracavernous Injection of Potassium Channel Openers in Monkeys and Dogs," Int. J. Impotence Res., 7: 41-48 (1995)		
	CAV	F. Trigo-Rocha et al.: "The Role of Cyclic Adenosine Monophosphate, Cyclic Guanosine Monophosphate, Endothelium and Nonadrenergic, Noncholinergic Neurotransmission in Canine Penile Erection," J. urology, 149: 872-887 (Apr. 1993)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/521,534-Conf. #8954
				Filing Date	August 31, 2005
				First Named Inventor	Peter Serno
				Art Unit	1615
				Examiner Name	H. N. Sheikh
Sheet	8	of	11	Attorney Docket Number	LeA35683 [83964(303989)]

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CAW	F. Trigo-Rocha et al.: "Nitric Oxide and cGMP: Mediators of Pelvic Nerve-Stimulated Erection in Dogs," J. Am. Phys., 264(2): H419-H422 (Feb. 1993)	
	CAX	F. Trigo-Rocha et al.: "Intracellular Mechanism of Penile Erection in Monkeys," Neurology and Urodynamics, 13: 71-80 (1994)	
	CAZ	M. Kozizumi et al.: "4(3H)-Quinazolines," Chugai Pharmaceutical Co., Ltd., Japan, Kokai, JP 52051378, Chem. Abstr. 87: 20171g (1977)	
	CBA	W. Draber and T. Fujita eds, <i>Rational Approaches to Structure, Activity, and Ecotoxicology of Agrochemicals</i> , CRC Press, Boca Ration, p. 4 (1992)	
	CBB	K. Korolkovas, <i>Essentials of Medicinal Chemistry</i> , 2 nd Edition, John Wiley & Sons, New York, pp. 78-82 (1988)	
	CBC	A. Gibson: "Phosphodiesterase 5 Inhibitors and Nitregic Transmission – From Zaprinast to Sildenafil," Eur. J. Pharmacol., 411: 1-10 (2001)	
	CBD	Katz et al.: J. Am. Coll. Cardiol., 36(3): 845-851 (2000)	
	CBE	I. Charles et al.: "Bicyclic Heterocycles with Nitrogen at the Ring Junction. Part 2. Application of the Dakin-West Reaction to the Synthesis of Imidazo-[5,1-f]-1,2,4-triazin-4(3H)-ones," J. Chem. Soc., Perkin Transactions 1, No. 5, pp. 1139-1146 (May 1980)	
	CBF	Rosen & McKenna, PDE-5 Inhibition and Sexual Response; Pharmacological Mechanisms and Clinical Outcomes, Annu. Rev. Sex. Res., 13: 36-88 (2002)	
	CBG	Abstract- XP-002382234 Gefunden im internet, Quick-Dissolving Tablets Made Easy with Pharmaburst, Special Delivery, SPI Pharma, pgs. 1-4 (2002)	
	CBH	Young, J.M., Vardenafil, Expert Opin. On Invest. Drugs, Vol. 11 (10): 1487-1496 (Oct., 2002)	
	CBI	Dobetti, "Fast-Melting Tablets: Developments and Technologies", Pharma. Tech. Int., 12(9): 32-42 (2000)	
	CBJ	Uekama et al., "Design and In Vitro Evaluation of Slow-Release Dosage Form of Pirentanide; Utility of β -Cyclodextrin," J. Pharm. Sc., Vol. 78, No. 3, pp. 244-248, (March 1990)	
	CBK	Ammar et al. "Improvement of some pharmaceutical properties of drugs by cyclodextrin complexation," Pharmazie, Vol. 51, pp. 42-51 (1996)	
	CBL	Stella et al., "Cyclodextrins: Their Future in Drug Formulation and Delivery," Pharma. Res. 14, 556-567 (1997)	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/521,534-Conf. #8954
				Filing Date	August 31, 2005
				First Named Inventor	Peter Serno
				Art Unit	1615
				Examiner Name	H. N. Sheikh
Sheet	9	of	11	Attorney Docket Number	LeA35683 [83964(303989)]

NON PATENT LITERATURE DOCUMENTS			
	CBM	Mura et al., "Improvement of Clonazepam Release from a Carbpol Hydrogel," Pharma. Acta Helv, 1992, 67, 282-288	
	CBN	Chino et al., "Sustained-Release of Drugs from Cyclodextrin-Containing Hydrogels," Proceed. Intern. Symp. Control. Rel. Bioact. Mater. Vol. 19, pp. 98-99 (1992)	
	CBO	Gionchedi et al., "Modification of the Dissolution Behaviour of a Water-insoluble Drug, Naftazone, for Zero-order Release Matrix Preparation," J. Pharm. Pharmacol. Vol. 46, pp. 476-480 (1994)	
	CBP	Otero-Espinar et al., "Oral bioavailability of naproxen- β -cyclodextrin inclusion compound," "International Journal of Pharmaceutics, 75, pp. 37-44 (1991)	
	CBQ	Bischoff et al., "The Oral Efficacy of Vardenafil Hydrochloride for Inducing Penile Erection in a Conscious Rabbit Model," J. Urology, Vol. 165, 1316-1318 (April, 2001)	
	CBR	Uckert, et al. "Characterization and Functional Relevance of Cyclic Nucleotide Phosphodiesterase Isoenzymes of the Human Prostate." J. Urol., 166: 2484-2490 (2001)	
	CBS	Montorsi, et al., "Review of Phosphodiesterases in the Urogenital System: New Directions for Therapeutic Intervention." J. Sex Med. 1: 322-336 (2004)	
	CBT	Lin, et al. " Phosphorodiesterases as Therapeutic Targets," Urology 61; 685-691 (2003)	
	CBU	H. A. Guess: "Epidemiology and Natural History of Benign Prostatic Hyperplasia," Urologic Clinics of North America, Vol. 22, No. 2, May 1995, pp. 247-261	
	CBV	M. C. Truss et al.: "Pharmakotherapie in der Urologie, " (index only) 2001	
	CBW	DJ. Carbone Jr. et al.: "Medical Therapy for Benign Prostatic Hyperplasia: Sexual Dysfunction and Impact on Quality of Life," International Journal of Impotence Research, No. 15, 2003, pp. 299-306	
	CBX	F. Sciarra et al.: "Role of Estrogens in Human Benign Prostatic Hyperplasia," Arch. Androl. 2000, Vol. 44, No. 3, pp. 213-220	
	CBY	F. Desgrandchamps: "Clinical Relevance of Growth Factor Antagonists in the Treatment of Benign Prostatic Hyperplasia," European Urology, 1997; 32 (supp. 1), pp. 28-31	
	CBZ	M. Gopalakrishnan et al.: "Potassium Channel Subtypes as Molecular Targets for Overactive Bladder and other Urological Disorders," Expert Opinion Ther. Targets, Vol. 8, No. 5, 2004, pp. 437-458	
	CCA	K-E. Andersson et al.: "Future Drugs for the Treatment of Benign Prostatic Hyperplasia," World J. Urol, Vol. 19, 2002, pp. 436-442	
	CCB	P. Drescher et al.: "Smooth Muscle Contractility in Prostatic Hyperplasia: Role of Cyclic Adenosine Monophosphate," The Prostate, Vol. 25, 1994, pp. 76-80	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/521,534-Conf. #8954
				Filing Date	August 31, 2005
				First Named Inventor	Peter Serno
				Art Unit	1615
				Examiner Name	H. N. Sheikh
Sheet	10	of	11	Attorney Docket Number	LeA35683 [83964(303989)]

NON PATENT LITERATURE DOCUMENTS			
	CCC	S. H. Soderling et al.: "Regulation of cAMP and cGMP Signaling: New Phosphodiesterases and New Functions," Current Opinion in Cell Biology, Nov. 12, 2000, pp. 174-179	
	CCD	J.J. Gillespie: "Phosphodiesterase-linked Inhibition of Nonmicturition Activity in the Isolated Bladder," BJU International, Vol. 93, 2004, pp. 1325-1332	
	CCE	D. Spina: "Phosphodiesterase-4 Inhibitors in the Treatment of Inflammatory Lung Disease," Drugs, Vol. 63, No. 23, 2003, pp. 2575-2594	
	CCF	C. Bardelle et al.: "Phosphodiesterase 4 Conformers: Preparation of Recombinant Enzymes and Assay for Inhibitors," Analytical Biochemistry, Vol. 275, 1999, pp. 148-155	
	CCG	R. S. Hansen et al.: "Purification of Two Calcium/Calmodulin-Dependent Forms of Cyclic Nucleotide Phosphodiesterase by Using Conformation-Specific Monoclonal Antibody Chromatography," Proc. Natl. Acad. Sci., Vol. 19, May 1982, pp. 2788-2792	
	CCH	C. A. Heid et al.: "Real Time Quantitative PCR," Genome Research, Vol. 6, 1996, pp. 986-994	
	CCI	Y. Jun et al.: "The Positive Effect of Sildenafil on LUTS from BPH While Treating ED," National Journal of Andrology, Vol. 10, No. 9, September 2004, 681-683	
	CCJ	Specification and pending claims of co-pending US application number 12/569,720	
	CKK	Baratti et al. "Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice." Behavioral Pharmacology, 10:8, pp. 731-737 (1999)	
	CCL	Schultheiss et al. "Cognitive Side Effects of Sildenafil: An Assessment Using Event-Related Brain Potentials." European Urology 37:2, page 82 (2000)	
	CCM	Giuliano et al. "Comparative Study of the Facilitator Proerectile Effect of Vardenafil and Sildenafil in Anaesthetised Rats." European Urology, supp. 5, No. 39, page 108	
	CCN	Sybertz et al. "Inhibitors of PDE1 and PDE5 cGMP phosphodiesterases: patents and therapeutic potential," Expert Opinion on Therapeutic Patents, Ashley Publications, vol. 7, no. 6, pp. 631-639 (1997)	
	CCO	Coste et al. "Characterization of a Novel Potent and Specific Inhibitor of Type V Phosphodiesterase." Biochemical Pharmacology 50(10) 1577-1585 (1995)	
	CCP	Terret et al. "Sildenafil (Viagra™), a Potent and Selective Inhibitor of Type 5 CGMP Phosphodiesterase with Utility for the Treatment of Male Erectile Dysfunction." Biorg. & Med. Chem. Letters, 6(15) 1819-1824 (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/521,534-Conf. #8954
				Filing Date	August 31, 2005
				First Named Inventor	Peter Serno
				Art Unit	1615
				Examiner Name	H. N. Sheikh
Sheet	11	of	11	Attorney Docket Number	LeA35683 [83964(303989)]

NON PATENT LITERATURE DOCUMENTS				
	CCQ	Loma "Preliminary report: use of sildenafil to treat dyskinesias in patients with Parkinson's disease." Neurology, Vol. 54, No. 7, supp. 3, pp. A90-A91 (2000)		
	CCR	Abstract and Machine translation of WO99/26946		
	CCS	Dale et al. Organic Process Research & Development 4,17-22 (2000)		
	CCT	Knaggs et al. Sulfonation, Kirk-Othmer Encyclopedia of Chemical Technology, 1-13 (2000)		
	CCU	Encyclopedia of Organic Reagents for Organic Synthesis, Bromine, and Iodine, John Wiley (2003)		